Do Black Boxes Work? US FDA Survey Would Test Impact On Prescribers
Executive Summary
Depending on who you ask, black box warnings can fail to curb inappropriate prescribing or scare off patients who would benefit from an effective therapy. FDA is proposing a provider survey to find out what perceptions really are.
You may also be interested in...
Takeda’s Uloric Gets CV Death Warning And Restricted Indication, But No REMS
Despite advisory committee pressure, US FDA stands firm against imposing REMS targeted at gout drug’s cardiovascular risks; however, Takeda must conduct utilization study to see if labeling changes impact prescribing patterns.
Pfizer's Pitch For Chantix Warning Reduction Focuses On Those With Mental Illness
Those patients need more options for smoking cessation, Pfizer says, but that is the group FDA most worries about when deciding whether to remove its boxed warning.
Mini-Sentinel Project Will Evaluate Impact Of LABA Label Change
The Mini-Sentinel medical products safety surveillance project will assess the health impact of FDA-mandated label warnings for use of long-acting beta agonists in asthma, Harvard Pilgrim Health Care Institute’s Richard Platt noted during a Sept. 15 webinar on Mini-Sentinel sponsored by the Brookings Institution.